RT Journal Article SR Electronic T1 Genomic analyses in a large clinical cohort reveal high prevalence of MECP2 variants associated with neuropsychiatric phenotypes in adulthood JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.31.21257498 DO 10.1101/2021.05.31.21257498 A1 Claudia Gonzaga-Jauregui A1 Alina Kurolap A1 Jeffrey Staples A1 Cristopher Van Hout A1 Daren Liu A1 Regeneron Genetics Center A1 Geisinger-Regeneron DiscovEHR Collaboration A1 Rodney Samaco A1 Karin Weiss A1 Hagit Baris Feldman YR 2021 UL http://medrxiv.org/content/early/2021/07/22/2021.05.31.21257498.abstract AB Purpose To evaluate the phenotypes of individuals with pathogenic and likely pathogenic variants in the MECP2 gene.Methods We surveyed exome sequencing data from a large clinical care cohort for deleterious variation in the MECP2 gene. We reviewed de-identified clinical information for these individuals to interrogate for neurodevelopmental and neuropsychiatric phenotypes.Results We identified pathogenic and likely pathogenic variants in MECP2 in individuals with typical and atypical Rett syndrome, and neuropsychiatric phenotypes, and estimate a prevalence of MECP2-associated disorders of 1 in 2,645 individuals. We observed a 7.45x increased relative risk of neuropsychiatric phenotypes, especially major depression, in adult individuals with deleterious variants in MECP2 without a diagnosis of Rett syndrome. Male individuals with missense pathogenic variants in MECP2 appear to have more severe neuropsychiatric phenotypes.Conclusions We identified and report individuals with heterozygous pathogenic variants in MECP2 and their phenotypes in a large clinical cohort. The observed prevalence of MECP2-associated disorders in our cohort is higher than estimated in the literature. Individuals with pathogenic variants in MECP2 can survive into adulthood but are at increased risk of developing neuropsychiatric disorders, mainly major depression. Pathogenic variation in MECP2 is a likely important contributor to neuropsychiatric disorders in the general population.Competing Interest StatementJS, DL, are full-time employees of the Regeneron Genetics Center and receive salary and stock options as part of compensation. All other authors have no conflict of interest to disclose.Funding StatementNo funding sources to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Proband 1 and her parents consented for research genomic studies through an institutional research study approved by the Rambam Helsinki Committee, study number 0038-14-RMB. DiscovEHR participants were consented in accordance with the Geisinger Health System (GHS) Institutional Review Board approved protocol, study number 2006-0258.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant genetic variants and deidentified phenotypic information are included in the manuscript and supplementary information. MECP2 reported variants will be deposited in ClinVar for public data access.